Merck to Return Vernakalant Rights – Analyst Blog

By | October 2, 2012
0 Comment

Merck ( MRK ) and Cardiome Pharma Corp. ( CRME ) recently announced that Cardiome will regain global marketing and development rights for the intravenous (IV) as well as the oral

Link:
Merck to Return Vernakalant Rights – Analyst Blog

Related posts:

  1. Merck’s Alzheimer’s Drug Progresses – Analyst Blog
  2. FDA Accepts Merck’s Sleep Drug NDA – Analyst Blog
  3. Merck KGaA Unit Announces Spin Off – Analyst Blog
  4. New Data on Merck’s Insomnia Drug – Analyst Blog